Orbital lymphoma

Surv Ophthalmol. 2019 Jan-Feb;64(1):45-66. doi: 10.1016/j.survophthal.2018.08.002. Epub 2018 Aug 23.

Abstract

Orbital lymphomas constitute 50-60% of ocular adnexal lymphomas. A total of 2211 cases of orbital lymphoma with a known subtype have been reported in the last 24 years (1994-2017). The vast majority of orbital lymphomas are of B-cell origin (97%), of which extranodal marginal zone B-cell lymphoma (EMZL) (59%) is the most common subtype, followed by diffuse large B-cell lymphoma (23%), follicular lymphoma (9%), and mantle cell lymphoma (5%). Orbital lymphoma is primarily a disease of the elderly. Gender distribution varies according to lymphoma subtype. However, extranodal marginal zone B-cell lymphoma (53%) and follicular lymphoma (75%) show a female predominance, whereas diffuse large B-cell lymphoma shows an even gender distribution. Mantle cell lymphoma has a striking male predominance of 80%. The histopathological subtype and the clinical stage of the disease are the best indicators of prognosis and patient outcome. Low-grade lymphomas such as extranodal marginal zone B-cell lymphoma and FL have a good prognosis, whereas high-grade lymphomas (diffuse large B-cell lymphoma and mantle cell lymphoma) are associated with a poor prognosis. When managing solitary low-grade lymphomas, radiotherapy is the treatment of choice. Chemotherapy, with or without radiotherapy, should be chosen for disseminated and high-grade lymphomas.

Keywords: characteristics; epidemiology; lymphoma; orbit; pathology; survival; treatment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Combined Modality Therapy
  • Global Health
  • Humans
  • Incidence
  • Lymphoma* / diagnosis
  • Lymphoma* / epidemiology
  • Lymphoma* / therapy
  • Orbit / diagnostic imaging*
  • Orbital Neoplasms* / diagnosis
  • Orbital Neoplasms* / epidemiology
  • Orbital Neoplasms* / therapy
  • Survival Rate / trends

Supplementary concepts

  • Orbital lymphoma